Intelligence / Healthtech / New Clinical Trials / Sinfatin S.L
Clinicaltrial registered12 Nov 2026
Sinfatin S.L
12 Nov 2026: Trial registered · Rimonabant for Cognitive Impairment in People With Post-COVID-19 Syndrome. Recorded in the ClinicalTrials.gov (US National Library of Medicine).
- Posted
- 12 Nov 2026
- Title
- Rimonabant for Cognitive Impairment in People With Post-COVID-19 Syndrome
- Conditions
- Post-COVID-19 Syndrome
- Phase
- Phase 2
- Study Type
- Interventional
- Status
- Not Yet Recruiting
- Countries
- Spain
- Country
- Spain
- Reference
- NCT07930637
- Location
- Spain
What this signal means
A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.
- United States leads with 192 of 777, then China (171).
- 777 added in the 30 days to 18 Nov 2026.
Reach them with AOS
Find the decision makers at Sinfatin S.L
AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.
Across AOS Research
Other records for Sinfatin S.L in our registers.
17 NovSinfatin S.Ltrial registered · HealthtechClinical3 NovSinfatin S.Ltrial registered · HealthtechClinical
More from Spain
New Clinical Trials
17 NovKinetic Performance S.L.trial registered · Effects of Zynamite S on Fatigue, Mood, Sleep, Safety, and Tolerability in Healthy AdultsClinical17 NovSinfatin S.Ltrial registered · Study of the Effects of Rimonabant on Functional Recovery in Subacute Stroke PatientsClinical16 NovAether Tech S.L.trial registered · Automated Oxygen Titration With the EMILY.AI Device During the Six-Minute Walk TestClinical13 NovDR Healthcare - biotexiatrial registered · Effect of Oral Diamine Oxidase on Symptoms Induced by Histamine Oral ChallengeClinical12 NovAether Tech S.L.trial registered · Automated Versus Manual Oxygen Titration With the EMILY.AI Device in Hospitalized Patients With Acute Respiratory FailureClinical12 NovNovo Nordisk A/Strial registered · A Research Study Investigating How Well Zenagamtide at Lower Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide at Lower Dose Levels in People With Type 2 Diabetes Treated With Metformin, Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i), or BothClinical
Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.